Otsuka’s Taiho reports Phase 3 fail for Duchenne muscular dystrophy drug
An Otsuka subsidiary said Tuesday that its experimental therapy for Duchenne muscular dystrophy has failed its Phase 3 primary endpoint in a group of ambulatory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
